Last reviewed · How we verify
NCT02620033
Impact of Yoga As Complementary Therapy in Patients Undergoing Radical Prostatectomy
NA trial testing Yoga therapy in Prostate Cancer in 30 participants. Completed in 31 December 2021.
29 June 2020
Quick facts
| Lead sponsor | The University of Texas Health Science Center at San Antonio |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 30 |
| Start date | 1 September 2015 |
| Primary completion | 29 June 2020 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Yoga therapy
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
The University of Texas Health Science Center at San Antonio
Who can join
Adults 30 to 80, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The researchers hope to learn if yoga complementary therapy would improve health-related quality of life, recovery of urinary continence and erectile function in patients who underwent prostate cancer surgery (i.e. radical prostatectomy). We hypothesized that in patients undergoing radical prostatectomy, preoperative and postoperative Yoga complementary therapy would improve health- related quality of life (HRQOL), recovery of urinary continence and erectile function. This two-arm, randomized controlled pilot study will compare Yoga intervention to usual care group. The aim is to evaluate the efficacy of Yoga complementary therapy on HRQOL in patients who underwent radical prostatectomy (RP). Yoga therapy will be given to the intervention group three times in a week for 6 weeks prior to surgery and then initiated 3 weeks after the surgery for another 6 weeks. The yoga exercise will be tailored to the participant's comfort level. As an exploratory analysis, we will evaluate pro-inflammatory and immunological markers.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery.
Angka L, Khan ST, Kilgour MK, Xu R, et al · · 2017 · cited 53× · PMID 28817109 · DOI 10.3390/ijms18081787 -
Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial.
Kaushik D, Shah PK, Mukherjee N, Ji N, et al · · 2022 · cited 40× · PMID 34815548 · DOI 10.1038/s41391-021-00470-w -
Effects of exercise on angiogenesis biomarkers in cancer patients: a systematic review and meta-analysis.
Wang J, He Y, Wang Z, Wang Z, et al · · 2025 · PMID 41583457 · DOI 10.3389/fimmu.2025.1705472
Verify or expand the search:
- PubMed search for NCT02620033
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Yoga therapy
Trials testing the same drug.
- NCT04433793 — Yoga Intervention for Reducing Fatigue in Cancer Patients · NA · completed
- NCT05820373 — The Effect of Yoga Therapy on Post-operative Side-effects Among Women With Breast Cancer · NA · completed
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other The University of Texas Health Science Center at San Antonio trials
Trials by the same sponsor.
- NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
- NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
- NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02620033 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
- Last refreshed: 20 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02620033.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing